Related Experiment Video

Updated: Jun 27, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Effects of Second-line Drugs on the Progression or Regression of Rheumatoid Nodules

B B Bautista1, E G Boyce, H R Schumacher

  • 1Division of Rheumatology, University of Pennsylvania School of Medicine (B.B.B., E.G.B., H.R.S.), Arthritis-Immunology Research Center, Philadelphia Veterans Affairs Medical Center (B.B.B., H.R.S.) and the Philadelphia College of Pharmacy and Science (E.G.B.), Philadelphia, Pennsylvania.

Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|December 17, 2008
PubMed

Insights

Second-line drugs show varied effects on rheumatoid nodules. Methotrexate was linked to nodule growth, while hydroxychloroquine and sulfasalazine promoted regression, independent of synovitis.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Immunology

Background:

  • Rheumatoid nodules are a common extra-articular manifestation of rheumatoid arthritis (RA).
  • The impact of second-line disease-modifying antirheumatic drugs (DMARDs) on rheumatoid nodules is not well-established.
  • Understanding drug effects on nodules is crucial for comprehensive RA management.

Purpose of the Study:

  • To evaluate the effects of various second-line DMARDs on the appearance, progression, and regression of rheumatoid nodules in RA patients.
  • To determine if drug-induced changes in nodules correlate with changes in synovitis.

Main Methods:

  • Open-label observational study of 119 RA patients over 20 years.
  • Analysis of nodule status (appearance, progression, regression) in 56 patients with nodules during treatment with 1-5 second-line DMARDs.
  • Correlation of nodule changes with specific drug use and synovitis activity.

Main Results:

  • A high prevalence of nodules (47%) was observed in the study population.
  • Methotrexate was associated with new nodule formation and progression in 68% of cases.
  • Hydroxychloroquine (36%) and sulfasalazine (32%) were most frequently linked to nodule regression or resolution.
  • Nodule changes did not consistently correlate with synovitis activity.

Conclusions:

  • Second-line DMARDs exert differential effects on rheumatoid nodules, distinct from their impact on synovitis.
  • Methotrexate may promote nodule formation/progression, whereas hydroxychloroquine and sulfasalazine may induce regression.
  • These findings suggest distinct drug mechanisms of action on this specific RA manifestation, warranting further investigation.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: